Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
| ▸ | PTGFR | P43088 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | CES1 | P23141 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11755472 | 0.98 | HDAC1 (0.60) | MAPTRXFP1HDAC1HDAC8PTGER1 | |
| SCHEMBL1981615 | 0.94 | FFAR4 (0.59) | MAPTRXFP1HDAC1HDAC8PTGER1 | |
| SCHEMBL11038837 | 0.90 | HDAC1 (0.58) | MAPTRXFP1HDAC1HDAC8PTGER1 | |
| SCHEMBL11041817 | 0.90 | HDAC1 (0.58) | MAPTRXFP1HDAC1HDAC8PTGER1 | |
| SCHEMBL11038941 | 0.90 | HDAC1 (0.58) | MAPTRXFP1HDAC1HDAC8PTGER1 | |
| SCHEMBL11038774 | 0.88 | HDAC1 (0.59) | MAPTHDAC1HDAC8FFAR4FFAR1 | |
| SCHEMBL30412030 | 0.88 | EPHX1 (0.59) | HDAC1HDAC8TAAR1FAAHCES1 | |
| SCHEMBL365336 | 0.87 | FFAR1 (0.70) | MAPTHDAC1HDAC8FFAR4FFAR1 | |
| SCHEMBL25233635 | 0.86 | KDM4E (0.54) | MAPTHDAC1HDAC8PTGER1PTGFR | |
| SCHEMBL29499605 | 0.86 | KDM4E (0.54) | MAPTHDAC1HDAC8PTGER1PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339668-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002044126-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0038343-B1 | SUBSTITUTED CARBOXYLIC CETO-ACIDS, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AND MEDICINAL COMPOSITIONS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1984-12-27 | — | — | EP | disclosed |
| EP-0051077-A1 | Substituted oxocarboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-05-12 | — | — | EP | disclosed |
| EP-0038343-A1 | SUBSTITUTED CARBOXYLIC CETO-ACIDS, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AND MEDICINAL COMPOSITIONS CONTAINING THEM. | BYK GULDEN LOMBERG CHEM FAB (DE) | 1981-10-28 | — | — | EP | disclosed |
| WO-1981001285-A1 | SUBSTITUTED CARBOXYLIC CETO-ACIDS,PROCESS FOR THE PREPARATION THEREOF,USE THEREOF AND MEDICINAL COMPOSITIONS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1981-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | PPIG, PIN1, PPIH | MAPT 1168/4885RXFP1 4875/4885HDAC1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.